Other targetable sarcomas
Veridiana Pires de Camargo1, Matt van de Rijn, Roberta Maestro
1Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract:
Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
Insights
This review explores targeted therapies for sarcoma, focusing on chromosomal changes like HDM2 and CDK4 amplification in dedifferentiated liposarcoma and other survival pathways for novel systemic treatments.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Aneuploid tumors, such as dedifferentiated liposarcoma, exhibit specific genetic alterations.
- Amplification of HDM2 and CDK4 are key chromosomal changes in these tumors, presenting therapeutic targets.
Purpose of the Study:
- To review target selection strategies for various sarcoma subtypes.
- To highlight novel techniques for identifying new systemic therapeutic approaches in sarcoma treatment.
Main Methods:
- Review of existing literature on sarcoma genetics and targeted therapies.
- Analysis of chromosomal abnormalities and cancer cell survival pathways.
- Examination of emerging techniques for therapeutic target identification.
Main Results:
- Specific chromosomal changes (e.g., HDM2, CDK4 amplification) offer targets for systemic therapy in aneuploid sarcomas.
- Cancer cell survival pathways (angiogenesis, apoptosis) represent additional therapeutic avenues.
- New techniques are being developed to identify novel treatment strategies.
Conclusions:
- Targeted therapies based on genetic alterations and survival pathways hold promise for sarcoma treatment.
- Continued research into novel techniques will expand therapeutic options for sarcoma patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...